Literature DB >> 31403868

Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.

Eric Pujade-Lauraine1, Susana Banerjee2, Sandro Pignata3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31403868     DOI： 10.1200/JCO.19.00194

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  32 in total

Review 1.  Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy.

Authors:  Alexandra Lainé; Travis T Sims; Olivia Le Saux; Isabelle Ray-Coquard; Robert L Coleman
Journal:  Curr Oncol Rep       Date:  2021-11-09       Impact factor: 5.075

2.  Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.

Authors:  Renaud Sabatier; Séverine Garnier; Arnaud Guille; Nadine Carbuccia; Jihane Pakradouni; José Adelaide; Magali Provansal; Maria Cappiello; Frédérique Rousseau; Max Chaffanet; Daniel Birnbaum; Emilie Mamessier; Anthony Gonçalves; François Bertucci
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

Review 3.  A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.

Authors:  Ahmad Saburi; Mohammad Saeed Kahrizi; Navid Naghsh; Hasti Etemadi; Ahmet İlhan; Ali Adili; Shadi Ghoreishizadeh; Rozita Tamjidifar; Morteza Akbari; Gülinnaz Ercan
Journal:  J Ovarian Res       Date:  2022-07-07       Impact factor: 5.506

4.  Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas.

Authors:  Roberta Affatato; Michela Chiappa; Federica Guffanti; Francesca Ricci; Laura Formenti; Robert Fruscio; Marta Jaconi; Maya Ridinger; Mark Erlander; Giovanna Damia
Journal:  Ther Adv Med Oncol       Date:  2022-05-31       Impact factor: 5.485

5.  Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma.

Authors:  Li Sun; Caixia Liu; Yun Li
Journal:  Comput Math Methods Med       Date:  2022-06-10       Impact factor: 2.809

6.  Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.

Authors:  Arun Kanakkanthara; Xiaonan Hou; Thomas L Ekstrom; Valentina Zanfagnin; Amelia M Huehls; Rebecca L Kelly; Husheng Ding; Melissa C Larson; George Vasmatzis; Ann L Oberg; Scott H Kaufmann; Aaron S Mansfield; S John Weroha; Larry M Karnitz
Journal:  Cancer Res       Date:  2021-11-22       Impact factor: 13.312

Review 7.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

8.  MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study.

Authors:  E Krasniqi; A Sacconi; G Blandino; P Vici; D Marinelli; L Pizzuti; M Mazzotta; D Sergi; E Capomolla; S Donzelli; M Carosi; A Bagnato; T Gamucci; S Tomao; C Natoli; P Marchetti; A Grassadonia; N Tinari; M De Tursi; E Vizza; G Ciliberto; L Landi; F Cappuzzo; M Barba
Journal:  Biomark Res       Date:  2021-07-13

9.  Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.

Authors:  Li-Yuan Feng; Bing-Bing Yan; Yong-Zhi Huang; Li Li
Journal:  Clin Epigenetics       Date:  2021-07-21       Impact factor: 6.551

10.  Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer.

Authors:  Olivia D Lara; Emine Bayraktar; Paola Amero; Shaolin Ma; Cristina Ivan; Wei Hu; Ying Wang; Lingegowda S Mangala; Prasanta Dutta; Pratip Bhattacharya; Ana Tari Ashizawa; Gabriel Lopez-Berestein; Cristian Rodriguez-Aguayo; Anil K Sood
Journal:  Oncotarget       Date:  2020-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.